These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10139672)

  • 1. Wellcome nixes Glaxo bid.
    Scott L
    Mod Healthc; 1995 Jan; 25(5):8. PubMed ID: 10139672
    [No Abstract]   [Full Text] [Related]  

  • 2. Glaxo and Wellcome.
    Nature; 1995 Mar; 374(6520):292. PubMed ID: 7885451
    [No Abstract]   [Full Text] [Related]  

  • 3. Glaxo bid 'reflects changing patterns of drug research'.
    Dickson D
    Nature; 1995 Jan; 373(6512):271. PubMed ID: 7830750
    [No Abstract]   [Full Text] [Related]  

  • 4. Merger of Glaxo Wellcome and SmithKline Beecham creates pharmaceutical giant.
    Abbott A
    Nature; 2000 Jan; 403(6767):232. PubMed ID: 10659813
    [No Abstract]   [Full Text] [Related]  

  • 5. 3TC: Glaxo Wellcome broadens patient assistance.
    AIDS Treat News; 1996 Jun; (no 248):6-7. PubMed ID: 11363595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical industry. Glaxo benches top manager.
    Aldhous P
    Nature; 1992 Feb; 355(6362):665. PubMed ID: 1741045
    [No Abstract]   [Full Text] [Related]  

  • 7. Celltech announces public offering.
    Ward M
    Nature; 1993 Nov; 366(6450):9. PubMed ID: 8232544
    [No Abstract]   [Full Text] [Related]  

  • 8. Big bucks buy up genome secrets.
    Coghlan A
    New Sci; 1995 Sep; 147(1997):4. PubMed ID: 11656461
    [No Abstract]   [Full Text] [Related]  

  • 9. Glaxo Wellcome expands Patient Assistance Program for 3TC.
    AIDS Patient Care STDS; 1996 Aug; 10(4):262. PubMed ID: 11361605
    [No Abstract]   [Full Text] [Related]  

  • 10. The Wellcome Laboratories: BES summer visit.
    George RE
    Biomed Eng; 1975 Nov; 10(11):414. PubMed ID: 1182258
    [No Abstract]   [Full Text] [Related]  

  • 11. Glaxo Wellcome epilepsy drug exhibits fatal side effects.
    Nat Biotechnol; 1997 May; 15(5):398. PubMed ID: 9131603
    [No Abstract]   [Full Text] [Related]  

  • 12. Glaxo move seen as 'unavoidable'.
    Dickson D
    Nature; 1995 Mar; 374(6517):6. PubMed ID: 7870169
    [No Abstract]   [Full Text] [Related]  

  • 13. Glaxo to close top-ranked institute.
    Balter M
    Science; 1997 Oct; 278(5337):379. PubMed ID: 9381135
    [No Abstract]   [Full Text] [Related]  

  • 14. Canadian High Court upholds Glaxo Wellcome AZT patent.
    AIDS Policy Law; 2002 Dec; 17(22):3. PubMed ID: 12510642
    [No Abstract]   [Full Text] [Related]  

  • 15. UK biotechnology. Biotechnology no longer Wellcome.
    Aldhous P
    Nature; 1990 Oct; 347(6293):507. PubMed ID: 2215672
    [No Abstract]   [Full Text] [Related]  

  • 16. Genentech loses appeal against Wellcome.
    McGourty C
    Nature; 1988 Nov; 336(6194):4. PubMed ID: 3141815
    [No Abstract]   [Full Text] [Related]  

  • 17. Wellcome Trust to double spending after sale of shares.
    Mundell I
    Nature; 1992 Jul; 358(6385):359. PubMed ID: 1641012
    [No Abstract]   [Full Text] [Related]  

  • 18. [Glaxo Wellcome, Germany, spends 60.000 DM for African HIV projects in Uganda and Malawi].
    Krankenpfl J; 1999 Dec; 37(12):479. PubMed ID: 10734858
    [No Abstract]   [Full Text] [Related]  

  • 19. Wellcome pledges $80 million for population studies.
    Nature; 1995 Mar; 374(6520):297. PubMed ID: 7885456
    [No Abstract]   [Full Text] [Related]  

  • 20. Glaxo goes back to basics in bid to meet new goals.
    Dickson D
    Nature; 1994 Feb; 367(6462):402. PubMed ID: 8107787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.